Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown. BMS announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback